Genvor Inc (GNVR) is an agricultural biotechnology company that develops peptide-based crop protection and plant performance solutions using its proprietary BioCypher Algorithm, an AI-driven peptide discovery platform. The company pursues a licensing-first commercialization model, forming strategic partnerships and joint development agreements with agricultural organizations that gain protected market rights to Genvor's peptide technologies in exchange for contributing regulatory expertise and distribution capabilities. Genvor has no disclosed product revenue as of fiscal year ended September 30, 2025, recorded a net loss of $5,589,041 ($0.22 per share, basic and diluted) for that period, and carried a working capital deficit of approximately $1,312,000 at September 30, 2025. The company's financials reflect a pre-revenue development stage, with cash used in operating activities of $555,717 for FY2025. Genvor participates in Bayer's Golden Ticket program, which provides resources for advancing its antimicrobial peptide technologies for crop disease resistance.

Revenue model

Licensing-first model: Genvor intends to generate revenue through licensing agreements and joint development agreements (JDAs) with agricultural partners who access its peptide technologies with protected market rights. No product revenue is disclosed in the FY2025 10-K filing.

Products and services

BioCypher Algorithm: proprietary AI-driven peptide discovery platform combining computational biology and machine learning. Synthetic peptide candidates include GV185, GV187, and AGM182, tested against fungal pathogens including Fusarium graminearum, Aspergillus flavus, Rhizopus stolonifer, and others. Antimicrobial peptides (AMPs) targeting crop disease resistance delivered as both biological sprays and genetic trait innovations.

Customers and end markets

Target end markets are crop protection and agricultural biotechnology, addressing plant diseases caused by fungi, bacteria, and toxins. Customers are intended to be agricultural organizations and industry partners seeking residue-free, peptide-based crop protection. Bayer is disclosed as a program partner via the Golden Ticket initiative. No paying customers or commercial contracts are disclosed in the FY2025 filing.

Value-chain role

Early-stage technology licensor and platform developer sitting upstream in the agricultural input value chain. Genvor discovers and validates peptide technologies, then relies on partners for regulatory development, field validation, and commercial distribution.

Geographic exposure

No specific geographic revenue breakdown disclosed in the FY2025 10-K. The filing references global agricultural markets and mentions EPA classification activity in the US context for comparable peptide technologies.

Competitors

Micropep Technologies, Hello Nature (formerly Italpollina), Sym Agro, Innatrix

Source: SEC 10-K, filed 2025-12-10

Industry: Agricultural Production-Crops